Miguel Muñoz (Miguel Munoz)

Publication Activity (10 Years)

Years Active: 2019-2023
Publications (10 Years): 13

Top Topics

Chemotherapy Induced

Vascular Endothelial Growth Factor

Top Venues

Journal of clinical medicine

BioMed research international

International journal of environmental research and public health

This page only lists publications with an associated author ORCID identifier.

Publications

Prema Robinson, Marisa Rosso, Miguel Muñoz
Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients. Journal of clinical medicine 12 (6) (2023)
Prema Robinson, Marisa Rosso, Miguel Muñoz
Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients. Journal of clinical medicine 12 (6) (2023)
Prema Robinson, Marisa Rosso, Miguel Muñoz
Neurokinin-1 Receptor Antagonists as a Potential Novel Therapeutic Option for Osteosarcoma Patients. Journal of clinical medicine 12 (6) (2023)
Rafael Coveñas, Francisco David Rodriguez, Prema Robinson, Miguel Muñoz
The Repurposing of Non-Peptide Neurokinin-1 Receptor Antagonists as Antitumor Drugs: An Urgent Challenge for Aprepitant. International journal of molecular sciences 24 (21) (2023)
Inmaculada Isorna, Miguel Ángel González-Moles, Miguel Muñoz, Francisco Esteban
Substance P and Neurokinin-1 Receptor System in Thyroid Cancer: Potential Targets for New Molecular Therapies. Journal of clinical medicine 12 (19) (2023)
Mario F Muñoz-Pinto, Sandro Argüelles, Marisa Rosso, Rafael Medina, Rafael Coveñas, Antonio Ayala, Miguel Muñoz
The Neurokinin-1 Receptor Is Essential for the Viability of Human Glioma Cells: A Possible Target for Treating Glioblastoma. BioMed research international 2022 (2022)
Prema Robinson, Emma Rodriguez, Miguel Muñoz
Substance P-Friend or Foe. Journal of clinical medicine 11 (13) (2022)
Rafael Coveñas, Miguel Muñoz
Involvement of the Substance P/Neurokinin-1 Receptor System in Cancer. Cancers 14 (14) (2022)
Riffat Mehboob, Syed Amir Gilani, Amber Hassan, null Sadaf, Imrana Tanvir, Shaista Javaid, Sidra Khalid, Sana Hasan, Humaira Waseem, Ahmad Alwazzan, Miguel Muñoz
Prognostic Significance of Substance P/Neurokinin 1 Receptor and Its Association with Hormonal Receptors in Breast Carcinoma. BioMed research international 2021 (2021)
Francisco Esteban, Pablo Ramos-García, Miguel Muñoz, Miguel Ángel González-Moles
Substance P and Neurokinin 1 Receptor in Chronic Inflammation and Cancer of the Head and Neck: A Review of the Literature. International journal of environmental research and public health 19 (1) (2021)
Miguel Muñoz, Rafael Coveñas
The Neurokinin-1 Receptor Antagonist Aprepitant: An Intelligent Bullet against Cancer? Cancers 12 (9) (2020)
Miguel Muñoz, Rafael Coveñas
The Neurokinin-1 Receptor Antagonist Aprepitant, a New Drug for the Treatment of Hematological Malignancies: Focus on Acute Myeloid Leukemia. Journal of clinical medicine 9 (6) (2020)
Miguel Muñoz, Marisa Rosso, Rafael Coveñas
Neurokinin-1 Receptor Antagonists against Hepatoblastoma. Cancers 11 (9) (2019)